Last reviewed · How we verify

NCT06555965

STXBP1 and SYNGAP1 Related Disorders Natural History Study

Recruiting now Last updated 29 October 2025
What this trial tests

trial testing Non-interventional study in Genetic Disease in 600 participants. Currently enrolling.

Timeline
30 August 2023
Primary endpoint
30 August 2028
30 December 2028

Quick facts

Lead sponsorChildren's Hospital of Philadelphia
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment600
Start date30 August 2023
Primary completion30 August 2028
Estimated completion30 December 2028
Sites5 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital of Philadelphia

Who can join

Eligibility, any sex, with Genetic Disease or STXBP1 Encephalopathy With Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out more about STXBP1 and SYNGAP1 related disorders. The information gathered by this study will be used to prepare for clinical treatment trials. The primary objective of the study is to better define and outline the clinical spectrum of STXBP1 and SYNGAP1 through detailed developmental, seizure, and quality of life assessments as an extension of routine clinical care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Non-interventional study

Trials testing the same drug.

Other recruiting trials for Genetic Disease

Currently open trials in the same condition.

Other Children's Hospital of Philadelphia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06555965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing